argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Core Insights - The ADHERE Study is the largest and most innovative clinical trial for chronic inflammatory demyelinating polyneuropathy (CIDP) published in The Lancet Neurology, demonstrating significant clinical improvements with VYVGART® Hytrulo [2][4] Company Overview - Argenx SE is a global immunology company focused on improving the lives of patients with severe autoimmune diseases, with VYVGART Hytrulo being a key product for treating CIDP [2][3] Product Information - VYVGART Hytrulo is the first and only FDA-approved neonatal Fc receptor (FcRn) blocker for CIDP, showing a 61% reduction in relapse risk and rapid onset of action [4][5][12] - The product combines efgartigimod alfa and hyaluronidase-qvfc, facilitating subcutaneous injection delivery of biologics [12] Clinical Trial Highlights - The ADHERE trial involved 322 adult patients, demonstrating a 69% clinical improvement rate and a 99% participation rate in the open-label extension [4][10] - The primary endpoint was met with a significant reduction in relapse risk (HR: 0.39, p<0.0001) and disease progression [4][10] Disease Context - CIDP is a rare autoimmune disease affecting the peripheral nervous system, with approximately 24,000 patients in the U.S. currently receiving treatment [13]